Rapid Pathogen Identification in Ventilated Patients With Pneumonia
The Taqman Microarray Card for Rapid Pathogen Identification in Ventilated Patients With Pneumonia
1 other identifier
observational
100
1 country
1
Brief Summary
Pneumonia, a serious infection of the lungs, is a common reason for Intensive Care Unit (ICU) admission. It may also develop as a significant complication of being on a mechanical ventilator. Although the clinical diagnosis is generally straight-forward to make, determining which organism is causing the infection (pathogen) presents a much greater challenge. Existing detection of pathogens relies on growing the organism under specific conditions in a microbiology laboratory. This process is slow, typically taking 48 to 72 hours, and is influenced by factors such as presence of antibiotics and the ease with which specific organisms can be grown. Conventional microbiology may only be positive less than 40% of cases of pneumonia and this means that patients are often treated with 'best guess' antibiotics. These antibiotics are generally broad spectrum, and risk the development of antibiotic resistance. Equally, organisms which are less commonly seen may not be covered by the initial antibiotic selection and may only be started once this organism is grown after 48 to 72 hours leading to delays in appropriate treatment. The aim of this study is to evaluate the performance of a new form of diagnostic test, using detection of pathogens by gene analysis rather than relying on growth. The investigators believe that this approach will be more rapid and more sensitive, and therefore likely to translate into more rapid and appropriate use of antibiotics.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 5, 2018
CompletedFirst Submitted
Initial submission to the registry
June 20, 2019
CompletedFirst Posted
Study publicly available on registry
June 24, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 16, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 23, 2019
CompletedNovember 19, 2019
November 1, 2019
1.5 years
June 20, 2019
November 18, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Time to result relative to conventional microbial culture
Comparison of the time to result returned to clinicians between the taqman array card and conventional microbial culture
5 days
Diagnostic performance compared to conventional culture
Comparison of sensitivity and negative predictive value of array card relative to conventional microbial culture
5 days
Secondary Outcomes (2)
Number and nature of organisms detected on taq-man array and not detected by conventional culture
5 days
Sensitivity of PCR from blood relative to bronchoalveolar lavage PCR
24 hours
Interventions
The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
Eligibility Criteria
Mechanically ventilated patients in intensive care with suspected pneumonia, from community acquired, hospital acquired and ventilator-associated sources.
You may qualify if:
- Age \>18
- Mechanically ventilated
- Treating clinician clinically suspects pneumonia and is planning to undertake diagnostic bronchoscopy and lavage
You may not qualify if:
- Inability to gain advice from a personal or professional consultee. Where a patient has capacity, declining consent for the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cambridge University Hospitals NHS Foundation Trustlead
- University of Cambridgecollaborator
- Public Health Englandcollaborator
Study Sites (1)
Cambridge University Hospitals NHS Foundation Trust
Cambridge, Cambs, CB2 0QQ, United Kingdom
Biospecimen
broncho-alveolar lavage, plasma
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vilas Navapurkar, MB ChB
Cambridge University Hospitals NHS Foundation Trust
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Research Associate and Honorary Consultant
Study Record Dates
First Submitted
June 20, 2019
First Posted
June 24, 2019
Study Start
February 5, 2018
Primary Completion
August 16, 2019
Study Completion
August 23, 2019
Last Updated
November 19, 2019
Record last verified: 2019-11
Data Sharing
- IPD Sharing
- Will not share